Plain-English translation of NCT06571825 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether elderly patients with acute myeloid leukemia (a serious blood cancer) who have achieved remission should receive a stem cell transplant or continue with -based medication therapy. Researchers want to understand which approach helps patients live longer and feel better. Both treatments are already used in clinical practice, but this study will compare them directly to see which works best for elderly patients.
Elderly patients with acute myeloid leukemia often have a very poor outlook, with only about 5–10% surviving 5 years. While this medication has improved how many patients go into remission, doctors are still unsure about the best next step—whether patients should receive a stem cell transplant or continue with medication alone. This trial exists to answer that important question and help guide treatment decisions.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be placed in one of two groups: either to receive a reduced-intensity stem cell transplant or to continue with -based medication therapy as your consolidation treatment. You will have regular clinic visits to receive your assigned treatment, undergo blood tests and imaging scans to monitor your response, and be followed for side effects and long-term outcomes. The study will track how well you respond and how long you survive to determine which approach works better for elderly patients like you.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China